Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy

International Journal of Clinical and Experimental Medicine

Volumn 5, Issue 2, 2012, Pages 154-164

  Benveniste, Helene ^a   Zhang, Shaonan ^b   Reinsel, Ruth A ^a   Li, Haifang ^a   Lee, Hedok ^a   Rebecchi, Mario ^a   Moore, William ^a   Johansen, Christoffer ^c   Rothman, Douglas L ^d   Bilfinger, Thomas V ^e  

^a STONY BROOK UNIVERSITY   (United States)

^b Stony Brook University   (United States)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Stony Brook Medicine   (United States)

Author keywords

Brain; Fatigue; Glutamate; Lung cancer; Proinflammatory cytokines; Proton magnetic resonance spectroscopy

Indexed keywords

CREATINE; CREATINE PHOSPHATE; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 6; N ACETYLASPARTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MALE; METABOLOMICS; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SCORING SYSTEM;

EID: 84859958916     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol 1997; 24: 277-287.
2. Kotler DP. Cachexia. Ann Intern Med 2000; 133: 622-634.
3. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis 2003; 21: 198-213.
4. Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN and Kaufman PA. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152.
5. Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol 2004; 5: 270-271.
6. Wefel JS, Vidrine DJ, Veramonti TL, Meyers CA, Marani SK, Hoekstra HJ, Hoekstra-Weebers JE, Shahani L and Gritz ER. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 2011; 117: 190-196.
7. Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am 2005; 43: 67-77.
8. Wang GJ, Volkow ND, Lau YH, Fowler JS, Meek AG, Park TL, Wong C, Roque CT, Adler AJ and Wolf AP. Glucose metabolic changes in nontu-moral brain tissue of patients with brain tumor following radiotherapy: a preliminary study. J Comput Assist Tomogr 1996; 20: 709-714.
9. Saykin AJ, Ahles TA and McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neu-ropsychiatry 2003; 8: 201-216.
10. Rothman DL, De Feyter HM, de Graaf RA, Mason GF and Behar KL. 13C MRS studies of neuro-energetics and neurotransmitter cycling in humans. NMR Biomed 2011; 24: 943-957.
11. SW. Automatic quantitation of local ized in vivo 1H spectra with LCModel. NMR Bio- med 2001; 14: 260-264.
12. Cella DF, Jacobsen PB, Orav EJ, Holland JC, Sil-berfarb PM and Rafla S. A brief POMS measure of distress for cancer patients. J Chronic Dis 1987; 40: 939-942.
13. D. Administration and Scoring Manual. Wechsler Adult Intelligence Scale, Third edition. San Antonio, TX, Psychological Corporation, 1997.
14. Detterbeck FC, Boffa DJ, Tanoue LT and Wilson LD. Details and difficulties regarding the new lung cancer staging system. Chest 2010; 137: 1172-1180.
15. Detterbeck FC, Boffa DJ and Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271.
16. Chang L, Jiang CS and Ernst T. Effects of age and sex on brain glutamate and other metabolites. Magn Reson Imaging 2009; 27: 142-145.
17. Atwell DM, Grichnik KP, Newman MF, Reves JG and McBride WT. Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. Ann Thorac Surg 1998; 66: 1145-1150.
18. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA and Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology 2008; 17: 1189-1195.
19. Cherrier MM, Aubin S and Higano CS. Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer. Psychooncology 2009; 18: 237-247.
20. Cherrier MM, Borghesani PR, Shelton AL and Higano CS. Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer 2010; 10: 1.
21. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J, Walot I, Boone K and Chlebowski R. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94: 592-597.
22. Eberling JL, Wu C, Tong-Turnbeaugh R and Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroi-mage 2004; 21: 364-371.
23. Jansen CE, Cooper BA, Dodd MJ and Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 2011; 19: 1647-1656.
24. Stone P, Richards M and Hardy J. Fatigue in patients with cancer. Eur J Cancer 1998; 34: 1670-1676.
25. Nail LM. Fatigue in patients with cancer. Oncol Nurs Forum 2002; 29: 537.
26. Stasi R, Abriani L, Beccaglia P, Terzoli E and Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer 2003; 98: 1786-1801.
27. Campos MP, Hassan BJ, Riechelmann R and Del Giglio A. Cancer-related fatigue: a review. Rev Assoc Med Bras 2011; 57: 211-219.
28. de Graaf RA, Chowdhury GM, Brown PB, Rothman DL and Behar KL. In situ 3D magnetic resonance metabolic imaging of microwave-irradiated rodent brain: a new tool for me-tabolomics research. J Neurochem 2009; 109: 494-501.
29. de Graaf RA, Mason GF, Patel AB, Behar KL and Rothman DL. In vivo 1H-[13C]-NMR spectroscopy of cerebral metabolism. NMR Biomed 2003; 16: 339-357.
30. Boumezbeur F, Mason GF, de Graaf RA, Behar KL, Cline GW, Shulman GI, Rothman DL and Petersen KF. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J Cereb Blood Flow Metab 2010; 30: 211-221.
31. Boumezbeur F, Petersen KF, Cline GW, Mason GF, Behar KL, Shulman GI and Rothman DL. The contribution of blood lactate to brain energy metabolism in humans measured by dynamic 13C nuclear magnetic resonance spectroscopy. J Neurosci 2010; 30: 13983-13991.
32. Borson S, Scanlan J, Friedman S, Zuhr E, Fields J, Aylward E, Mahurin R, Richards T, Anzai Y, Yukawa M and Yeh S. Modeling the impact of COPD on the brain. Int J Chron Obstruct Pulmon Dis 2008; 3: 429-434.
33. Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 1998; 39: 53-60.
34. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T and Ogura T. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095-1098.
35. Tonnesen E, Wanscher M, Hohndorf K, Bendtzen K, Hansen MB, Diamant M, Hansen GL and Toft P. Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery. Acta Anaesthesiol Scand 1993; 37: 410-414.
36. Martinet N, Charles T, Vaillant P, Vignaud JM, Lambert J and Martinet Y. Characterization of a tumor necrosis factor-alpha inhibitor activity in cancer patients. Am J Respir Cell Mol Biol 1992; 6: 510-515.
37. Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D and Vansteenkiste J. Association between 18F-fluoro -2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol 2009; 4: 822-828.
38. van Baardwijk A, Dooms C, van Suylen RJ, Ver-beken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J and De Ruysscher D. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: 1392-1398.
39. Scheibel RS, Valentine AD, O'Brien S and Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004; 16: 185-191.
40. Malik UR, Makower DF and Wadler S. Interferon-mediated fatigue. Cancer 2001; 92: 1664-1668.
41. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 1999; 461: 75-81.
42. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA and Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365: 87-91.
43. Reichenberg A, Gorman JM and Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005; 19 Suppl 3: S174-S178.
44. Majer M, Welberg LA, Capuron L, Pagnoni G, Raison CL and Miller AH. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008; 22: 870-880.